GOVX: Zika platform at CENTER of NIH $100M trials. NOTE: The NIH news today concerning the HIV vax effort put GOVX in the top tier of HIV related bio/pharmas The NIH is also placing a priority on the GOVX DNA based platform for the Zika vax trials that is now kicking into high gear. My standing advice is to buy 500,000 shares of GOVX and sit back. If it drops, buy more. Here is the NIH Zika news: http://hosted.ap.org/dynamic/stories/U/US_MED_ZIKA_VACCINE?SITE=AP&SECTION=HOME&TEMPLATE=DEFAULT&CTIME=2017-03-31-14-55-50 GeoVax: DNA based Zika vax: http://www.fiercepharma.com/vaccines/geovax-breaks-into-zika-vaccine-realm-promising-preclinical-data